U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
NEW YORK - Paynela, a healthcare financing company specializing in AI-driven claim processing, announced Wednesday the appointment of William Febbo to its Board of Directors, effective immediately.
Febbo brings over 30 years of experience in healthcare technology and pharmaceutical patient assistance programs. He served as Chief Executive Officer and Director of OptimizeRX Corporation (NASDAQ:OPRX) from 2016 to 2025, where he transformed the company from a single point-of-care product into a comprehensive omnichannel platform serving major pharmaceutical companies. Under his leadership, OPRX achieved significant growth, with recent data showing 20.66% year-over-year revenue growth and maintaining a strong financial position with a current ratio of 2.82. The company’s stock has demonstrated remarkable performance, surging over 125% in the past six months. According to InvestingPro, which offers comprehensive analysis of 1,400+ US stocks, OPRX maintains a "GOOD" overall financial health score.
"His deep expertise in pharmaceutical patient assistance programs, digital health technology, and his proven track record of scaling healthcare companies make him an invaluable addition to our team," said Mary-Beth Macaluso, CEO of Paynela, in a press release statement.
Febbo currently serves as Office of the Chairman at Oxbridge Health and on the Board of Directors at LifeMD. He is also Faculty/Mentor at MIT’s LinQ program, supporting healthcare entrepreneurs and scientists.
The appointment comes as Paynela continues to expand its AI-driven healthcare financing solutions. The company was recently named a 2024 AWS Generative AI Trailblazer for its automated healthcare data review system, which has reportedly increased processing speed by 320 times through the use of generative AI technology.
Founded in 2024, Paynela offers services including NelaClaim, an AI-driven claims processing engine; NelaPay, a direct-to-patient payment system; and NelaView, a patient portal for managing healthcare funds. For detailed financial analysis and investment insights on healthcare technology companies like OPRX and its peers, visit InvestingPro, where you’ll find exclusive ProTips, Fair Value assessments, and comprehensive financial health metrics.
Febbo previously founded MedPanel, LLC, a healthcare market research firm, and Plexuus, LLC, which provided payment solutions for medical professionals. He holds a Bachelor of Science in International Studies and Spanish from Dickinson College.
In other recent news, OptimizeRx Corp reported its first-quarter 2025 earnings with a revenue of $21.9 million, surpassing analysts’ forecasts of $19.1 million. This strong revenue performance comes despite a slight miss in earnings per share. Additionally, JMP Securities has revised its financial forecasts for the company, raising the 2025 revenue projection to $103.5 million, a 12% year-over-year growth. The adjusted EBITDA estimate for the same year was also increased to $14 million, reflecting a 19% year-over-year rise. Analyst firm Stifel has raised its price target for OptimizeRx shares to $16 from $12, maintaining a Buy rating, following insights shared by the company’s CEO and CFO at a recent conference. Meanwhile, JMP Securities also increased its price target for the company to $14 from $11, reiterating a Market Outperform rating. In corporate governance developments, OptimizeRx appointed its CEO, Steve Silvestro, to the Board of Directors, effective June 20, 2025. These updates highlight the company’s strategic direction and financial adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.